COZAAR TABLET

Land: Kanada

Sprache: Englisch

Quelle: Health Canada

Wirkstoff:

LOSARTAN POTASSIUM

Verfügbar ab:

ORGANON CANADA INC.

ATC-Code:

C09CA01

INN (Internationale Bezeichnung):

LOSARTAN

Dosierung:

50MG

Darreichungsform:

TABLET

Zusammensetzung:

LOSARTAN POTASSIUM 50MG

Verabreichungsweg:

ORAL

Einheiten im Paket:

28/30/50

Verschreibungstyp:

Prescription

Therapiebereich:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Produktbesonderheiten:

Active ingredient group (AIG) number: 0127971003; AHFS:

Berechtigungsstatus:

APPROVED

Berechtigungsdatum:

2005-06-07

Fachinformation

_COZAAR_
_®_
_ (losartan potassium) _
_Page 1 of 44_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
COZAAR®
losartan potassium tablets
25, 50 and 100 mg
Angiotensin II Receptor Antagonist
ORGANON CANADA INC.
16766 route Transcanadienne
Kirkland, QC Canada H9H 4M7
www.organon.ca
Date of Initial Authorization:
DEC 31, 1995
Date of Revision:
July 6, 2022
Submission Control Number: 260621
_ _
_®_
_ N.V. Organon. Used under license. _
© 2022 Organon group of companies. All rights reserved.
_ _
_ _
_COZAAR_
_®_
_ (losartan potassium) _
_Page 2 of 44_
RECENT MAJOR LABEL CHANGES
None
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES............................................................................................
2
TABLE OF CONTENTS
..............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
4
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
..........................................................................................................
4
1.2
Geriatrics...........................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND
ADMINISTRATION.................................................................................
5
4.1
Dosing Considerations
.......................................................................................
5
4.2
Recommended Dose and Dosage
Adjustment..................................................... 5
4.4
Administration..............................